Clinical Trial Update: Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma [Phase 1]

View source ↗

Summary

Phase 1 study assessing the efficacy and safety of GSK3923868 inhalation powder during experimental rhinovirus infection in adults with mild asthma. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK3923868 inhalation powder (GSK3923868)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED